TriangleAsciminib (NCT06236724)
Asciminib trial for Chronic Myeloid Leukemia (NCT06236724). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with Philadelphia-chromosome-positive or BCR::ABL1-positive chronic myeloid leukemia within twelve months of diagnosis, in early chronic phase. Brief previous treatment is allowed; later chronic phase, accelerated disease and blast phase are excluded, with a chromosome-only exception.
The idea: oral asciminib blocks BCR::ABL1 growth signaling through a distinct binding pocket. Participants take tablets daily. Researchers assess molecular responses, safety, progression and survival, including whether deep responses last and treatment-free remission occurs.
This phase 2 study plans 150 patients. Elias Jabbour leads MD Anderson’s recruiting Houston site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.